Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ascorbate-meglumine
- Development stage
- Unknown
- Lead developer
- LadeRx
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Ascorbate-meglumine** is an investigational parenteral small-molecule salt of ascorbate and meglumine developed by LadeRx. It is supplied as a dried composition for reconstitution and intravenous administration and is being evaluated as an MRI-detectable adjunctive therapeutic administered around stereotactic radiosurgery for patients with limited brain metastases from extracranial primary cancers. The registered Phase 1 study assesses dose escalation, safety, pharmacokinetics, MRI contrast enhancement, and use alongside stereotactic radiosurgery. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06433791))
- Other names
- ascorbate + megluminemeglumine ascorbate
Beyond the preview
Go deeper on ascorbate-meglumine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ascorbate-meglumine.